title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
Stocks That Hit 52-Week Lows On Wednesday,20220511T162815,https://www.benzinga.com/markets/options/22/05/27141482/52-weeks-high-and-low-article,AADI,0.006905,Neutral,-0.008683
Stocks That Hit 52-Week Lows On Thursday,20220428T193101,https://www.benzinga.com/markets/options/22/04/26872967/52-weeks-high-and-low-article,AADI,0.00644,Neutral,-0.00583
Why Keysight Technologies Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket - Keysight Techs  ( NYSE:KEYS ) ,20240821T094726,https://www.benzinga.com/news/24/08/40480200/why-keysight-technologies-shares-are-trading-higher-by-around-11-here-are-20-stocks-moving-premarket,AADI,0.167322,Somewhat-Bearish,-0.20416
"Earnings Scheduled For May 12, 2022",20220512T085523,https://www.benzinga.com/news/earnings/22/05/27156592/earnings-scheduled-for-may-12-2022,AADI,0.017681,Neutral,-0.0818
Stocks That Hit 52-Week Lows On Wednesday,20220427T184104,https://www.benzinga.com/markets/options/22/04/26844275/52-weeks-high-and-low-article,AADI,0.006956,Neutral,0.001337
Why Is Cancer-Focused Aadi Bioscience Stock Trading Higher On Friday? - Aadi Bioscience  ( NASDAQ:AADI ) ,20241220T134335,https://www.benzinga.com/general/biotech/24/12/42615874/why-is-cancer-focused-aadi-bioscience-stock-trading-higher-on-friday,AADI,0.517168,Somewhat-Bullish,0.165726
"Aadi Bioscience, Inc.  ( AADI )  Reports Q3 Loss, Tops Revenue Estimates",20241106T141005,https://www.zacks.com/stock/news/2365082/aadi-bioscience-inc-aadi-reports-q3-loss-tops-revenue-estimates,AADI,0.408949,Neutral,0.101886
This American Express Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - American Express  ( NYSE:AXP ) ,20240821T134518,https://www.benzinga.com/news/24/08/40485954/this-american-express-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-wednesday,AADI,0.382925,Somewhat-Bullish,0.346345
Why Is Aadi Bioscience Stock Trading Lower On Wednesday? - Aadi Bioscience  ( NASDAQ:AADI ) ,20240821T130712,https://www.benzinga.com/general/biotech/24/08/40484716/cancer-focused-aadi-bioscience-stock-plunges-as-solid-tumor-trial-falls-short-of-expectations,AADI,0.428632,Neutral,0.066093
"Aadi Bioscience, Inc.  ( AADI )  Reports Q2 Loss, Lags Revenue Estimates",20240807T131005,https://www.zacks.com/stock/news/2317874/aadi-bioscience-inc-aadi-reports-q2-loss-lags-revenue-estimates,AADI,0.400265,Neutral,0.046596
Myriad Genetics  ( MYGN )  Surpasses Q2 Earnings and Revenue Estimates,20240806T223007,https://www.zacks.com/stock/news/2317514/myriad-genetics-mygn-surpasses-q2-earnings-and-revenue-estimates,AADI,0.205225,Neutral,0.0
Is Align Technology  ( ALGN )  Outperforming Other Medical Stocks This Year?,20240506T134011,https://www.zacks.com/stock/news/2268708/is-align-technology-algn-outperforming-other-medical-stocks-this-year,AADI,0.489394,Somewhat-Bullish,0.219812
Is Aadi Bioscience  ( AADI )  Stock Outpacing Its Medical Peers This Year?,20240403T134012,https://www.zacks.com/stock/news/2249731/is-aadi-bioscience-aadi-stock-outpacing-its-medical-peers-this-year,AADI,0.717937,Bullish,0.383036
Is Aadi Bioscience  ( AADI )  Outperforming Other Medical Stocks This Year?,20240318T134011,https://www.zacks.com/stock/news/2242125/is-aadi-bioscience-aadi-outperforming-other-medical-stocks-this-year,AADI,0.733479,Bullish,0.36786
Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology  ( SGO ) ,20240317T120000,https://www.prnewswire.com/news-releases/aadi-bioscience-presents-new-subgroup-analysis-of-patients-with-advanced-malignant-pecoma-of-gynecologic-origin-treated-with-nab-sirolimus-at-society-of-gynecologic-oncology-sgo-302090852.html,AADI,0.088363,Neutral,0.047693
"Aadi Bioscience, Inc.  ( AADI )  Reports Q4 Loss, Misses Revenue Estimates",20240313T130502,https://www.zacks.com/stock/news/2239823/aadi-bioscience-inc-aadi-reports-q4-loss-misses-revenue-estimates,AADI,0.399204,Neutral,0.046528
Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update,20240313T120000,https://www.prnewswire.com/news-releases/aadi-bioscience-announces-financial-results-for-the-fourth-quarter-and-full-year-2023-and-provides-corporate-update-302087370.html,AADI,0.150404,Neutral,0.025273
"NGM Biopharmaceuticals  ( NGM )  Reports Q4 Loss, Lags Revenue Estimates",20240311T213004,https://www.zacks.com/stock/news/2238868/ngm-biopharmaceuticals-ngm-reports-q4-loss-lags-revenue-estimates,AADI,0.205225,Neutral,0.0
"Evogene  ( EVGN )  Reports Q4 Loss, Misses Revenue Estimates",20240307T142003,https://www.zacks.com/stock/news/2237240/evogene-evgn-reports-q4-loss-misses-revenue-estimates,AADI,0.208764,Neutral,0.0
Ocuphire  ( OCUP )  to Report Q4 Earnings: What's in the Cards?,20240304T131800,https://www.zacks.com/stock/news/2235142/ocuphire-ocup-to-report-q4-earnings-whats-in-the-cards,AADI,0.179343,Neutral,-0.089095
"Why BioVie Shares Are Trading Lower By Around 42%; Here Are 20 Stocks Moving Premarket - Adial Pharmaceuticals  ( NASDAQ:ADIL ) , Aadi Bioscience  ( NASDAQ:AADI ) ",20240304T130436,https://www.benzinga.com/news/24/03/37453547/why-biovie-shares-are-trading-lower-by-around-42-here-are-20-stocks-moving-premarket,AADI,0.146025,Neutral,0.133643
Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARROÂ® for the Treatment of Malignant PEComa,20240301T210800,https://www.prnewswire.com/news-releases/aadi-bioscience-announces-publication-of-long-term-efficacy-and-safety-data-further-supporting-fyarro-for-the-treatment-of-malignant-pecoma-302077584.html,AADI,0.109622,Neutral,0.048718
"Ginkgo Bioworks Holdings, Inc.  ( DNA )  Reports Q4 Loss, Misses Revenue Estimates",20240229T232002,https://www.zacks.com/stock/news/2234274/ginkgo-bioworks-holdings-inc-dna-reports-q4-loss-misses-revenue-estimates,AADI,0.205807,Neutral,0.0
Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology  ( ASCO )  Genitourinary  ( GU )  Cancers Symposium,20240126T210500,https://www.prnewswire.com/news-releases/aadi-bioscience-announces-poster-presentations-at-the-2024-american-society-of-clinical-oncology-asco-genitourinary-gu-cancers-symposium-302045933.html,AADI,0.17715,Neutral,0.070555
Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology  ( ASCO )  Gastrointestinal  ( GI )  Cancers Symposium,20240119T210500,https://www.prnewswire.com/news-releases/aadi-bioscience-announces-poster-presentations-at-the-2024-american-society-of-clinical-oncology-asco-gastrointestinal-gi-cancers-symposium-302039765.html,AADI,0.142144,Neutral,0.060077
"Gastroenteropancreatic Neuroendocrine Tumors Market to Showcase a Significant Growth by 2032, Evaluates DelveInsight | Key Players - Eli Lilly and Company, Phanes Therapeutics, Camurus AB, Advanced Accelerator Applications, PharmaMar",20240111T220100,https://www.prnewswire.com/news-releases/gastroenteropancreatic-neuroendocrine-tumors-market-to-showcase-a-significant-growth-by-2032-evaluates-delveinsight--key-players---eli-lilly-and-company-phanes-therapeutics-camurus-ab-advanced-accelerator-applications-pharma-302032286.html,AADI,0.025139,Neutral,0.106773
"Top 3 Health Care Stocks That Are Preparing To Pump This Month - Durect  ( NASDAQ:DRRX ) , Aadi Bioscience  ( NASDAQ:AADI ) ",20231218T123929,https://www.benzinga.com/trading-ideas/long-ideas/23/12/36279779/top-3-health-care-stocks-that-are-preparing-to-pump-this-month,AADI,0.373378,Somewhat-Bearish,-0.212403
Cancer Player Aadi Bioscience Downgraded: Analyst Highlights 'Worse Than Expected' Response Rates - Aadi Bioscience  ( NASDAQ:AADI ) ,20231215T191633,https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36262600/cancer-player-aadi-bioscience-downgraded-analyst-highlights-worse-than-expected-res,AADI,0.470894,Neutral,0.139942
"Dow Edges Higher; Darden Restaurants Earnings Top Views - Battalion Oil  ( AMEX:BATL ) , Aadi Bioscience  ( NASDAQ:AADI ) ",20231215T172536,https://www.benzinga.com/news/earnings/23/12/36261944/dow-edges-higher-darden-restaurants-earnings-top-views,AADI,0.126119,Neutral,0.126244
"US Stocks Mixed; Costco Posts Upbeat Earnings - Battalion Oil  ( AMEX:BATL ) , Aadi Bioscience  ( NASDAQ:AADI ) ",20231215T144144,https://www.benzinga.com/news/earnings/23/12/36258141/us-stocks-mixed-costco-posts-upbeat-earnings,AADI,0.128135,Neutral,0.127185
Why Is Anti-Cancer Focused Aadi Bioscience  ( AADI )  Stock Trading Lower Today? - Aadi Bioscience  ( NASDAQ:AADI ) ,20231215T141537,https://www.benzinga.com/markets/equities/23/12/36254662/why-is-anti-cancer-focused-aadi-bioscience-stock-trading-lower-today,AADI,0.345674,Neutral,0.090395
"Why Getaround Shares Are Trading Higher By Around 86%; Here Are 20 Stocks Moving Premarket - Aileron Therapeutics  ( NASDAQ:ALRN ) , Aadi Bioscience  ( NASDAQ:AADI ) ",20231215T131709,https://www.benzinga.com/news/23/12/36255748/why-getaround-shares-are-trading-higher-by-around-86-here-are-20-stocks-moving-premarket,AADI,0.159043,Neutral,0.029052
"How Much Upside is Left in Aadi Bioscience, Inc.  ( AADI ) ? Wall Street Analysts Think 509.98%",20231129T145509,https://www.zacks.com/stock/news/2190904/how-much-upside-is-left-in-aadi-bioscience-inc-aadi-wall-street-analysts-think-50998,AADI,0.288214,Bullish,0.360626
Colorectal Cancer Treatment Drug Market to Show Immense Growth During the Study Period  ( 2019-2032 )  | DelveInsight,20231121T220100,https://www.prnewswire.com/news-releases/colorectal-cancer-treatment-drug-market-to-show-immense-growth-during-the-study-period-20192032--delveinsight-301994315.html,AADI,0.023102,Neutral,-0.075172
"Stocks That Hit 52-Week Lows On Wednesday - Bristol-Myers Squibb Company Common Stock  ( NYSE:BMY ) , SenesTech, Inc. - Common Stock  ( NASDAQ:SNES ) ",20231004T160117,https://www.benzinga.com/markets/options/23/10/35092508/stocks-that-hit-52-week-lows-on-wednesday,AADI,0.012708,Neutral,0.004414
Executive Chairman of Aadi Bioscience Sold $179K In Stock - Aadi Bioscience  ( NASDAQ:AADI ) ,20231004T150102,https://www.benzinga.com/news/23/10/35091744/executive-chairman-of-aadi-bioscience-sold-179k-in-stock,AADI,0.478939,Somewhat-Bullish,0.275605
"Aadi Bioscience Appoints Dave Lennon, Ph.D. as President and Chief Executive Officer",20231002T120000,https://www.prnewswire.com/news-releases/aadi-bioscience-appoints-dave-lennon-phd-as-president-and-chief-executive-officer-301944034.html,AADI,0.158728,Neutral,0.054824
"Aadi Bioscience, Inc.  ( AADI )  Reports Q2 Loss, Tops Revenue Estimates",20230809T131505,https://www.zacks.com/stock/news/2134269/aadi-bioscience-inc-aadi-reports-q2-loss-tops-revenue-estimates,AADI,0.397098,Neutral,0.070536
Aadi Bioscience Announces Financial Results for the Second Quarter 2023 and Provides Corporate Update,20230809T120000,https://www.prnewswire.com/news-releases/aadi-bioscience-announces-financial-results-for-the-second-quarter-2023-and-provides-corporate-update-301896367.html,AADI,0.186378,Neutral,0.036345
"C4 Therapeutics, Inc.  ( CCCC )  Reports Q2 Loss, Lags Revenue Estimates",20230808T124008,https://www.zacks.com/stock/news/2133554/c4-therapeutics-inc-cccc-reports-q2-loss-lags-revenue-estimates,AADI,0.202932,Neutral,0.0
"Hypertension Market to Accelerate Positively, Estimates DelveInsight | Key Companies Active in the Market - Novartis, Bayer, Merck, Insmed, Acceleron, AbbVie, Alnylam, Apnimed, AstraZeneca, Gossamer Bio",20230719T210100,https://www.prnewswire.com/news-releases/hypertension-market-to-accelerate-positively-estimates-delveinsight--key-companies-active-in-the-market---novartis-bayer-merck-insmed-acceleron-abbvie-alnylam--apnimed-astrazeneca-gossamer-bio-301880558.html,AADI,0.024801,Neutral,-0.004523
"Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - FibroGen  ( NASDAQ:FGEN ) , Aadi Bioscience  ( NASDAQ:AADI ) ",20230718T125413,https://www.benzinga.com/trading-ideas/long-ideas/23/07/33265738/top-5-health-care-stocks-which-could-rescue-your-portfolio-this-month,AADI,0.33628,Bullish,0.374518
Aadi Bioscience Insider Trades Send a Signal - Aadi Bioscience  ( NASDAQ:AADI ) ,20230707T150206,https://www.benzinga.com/news/23/07/33148834/aadi-bioscience-insider-trades-send-a-signal,AADI,0.514619,Somewhat-Bullish,0.287604
Executive Chairman of Aadi Bioscience Sold $279K In Stock - Aadi Bioscience  ( NASDAQ:AADI ) ,20230606T150546,https://www.benzinga.com/news/23/06/32740238/executive-chairman-of-aadi-bioscience-sold-279k-in-stock,AADI,0.509589,Somewhat-Bullish,0.285976
"Aadi Bioscience, Inc.  ( AADI )  Reports Q1 Loss, Tops Revenue Estimates",20230510T131506,https://www.zacks.com/stock/news/2093343/aadi-bioscience-inc-aadi-reports-q1-loss-tops-revenue-estimates,AADI,0.396052,Neutral,0.070403
"Atyr Pharma  ( LIFE )  Reports Q1 Loss, Misses Revenue Estimates",20230509T211515,https://www.zacks.com/stock/news/2092699/atyr-pharma-life-reports-q1-loss-misses-revenue-estimates,AADI,0.211191,Neutral,0.0
"Immuneering Corporation  ( IMRX )  Reports Q1 Loss, Misses Revenue Estimates",20230504T232511,https://www.zacks.com/stock/news/2090565/immuneering-corporation-imrx-reports-q1-loss-misses-revenue-estimates,AADI,0.205807,Neutral,0.0
Aadi Bioscience to Present Multiple Posters on nab-Sirolimus at the 2023 American Association for Cancer Research  ( AACR )  Annual Meeting,20230414T170900,https://www.prnewswire.com/news-releases/aadi-bioscience-to-present-multiple-posters-on-nab-sirolimus-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting-301797888.html,AADI,0.062926,Neutral,-0.03007
"Aadi Bioscience, Inc.  ( AADI )  Reports Q4 Loss, Tops Revenue Estimates",20230328T131503,https://www.zacks.com/stock/news/2071261/aadi-bioscience-inc-aadi-reports-q4-loss-tops-revenue-estimates,AADI,0.393977,Neutral,0.070139
"Aadi Bioscience Appoints Mohammad Hirmand, M.D. to Board of Directors",20230327T120000,https://www.prnewswire.com/news-releases/aadi-bioscience-appoints-mohammad-hirmand-md-to-board-of-directors-301781997.html,AADI,0.130217,Neutral,-0.040084
Aadi Bioscience Presents Clinical Data from PRECISION 1 and AMPECT Trials at the Society of Gynecological Oncology  ( SGO )  Annual Meeting on Women's Cancer,20230326T180000,https://www.prnewswire.com/news-releases/aadi-bioscience-presents-clinical-data-from-precision-1-and-ampect-trials-at-the-society-of-gynecological-oncology-sgo-annual-meeting-on-womens-cancer-301781585.html,AADI,0.1789,Neutral,0.112441
"Geron  ( GERN )  Reports Q4 Loss, Misses Revenue Estimates",20230316T213505,https://www.zacks.com/stock/news/2066957/geron-gern-reports-q4-loss-misses-revenue-estimates,AADI,0.208764,Neutral,0.0
"Caribou Biosciences, Inc.  ( CRBU )  Reports Q4 Loss, Misses Revenue Estimates",20230310T002504,https://www.zacks.com/stock/news/2063886/caribou-biosciences-inc-crbu-reports-q4-loss-misses-revenue-estimates,AADI,0.205807,Neutral,0.0
Mirati Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates,20230228T210100,https://www.prnewswire.com/news-releases/mirati-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-recent-corporate-updates-301758465.html,AADI,0.021484,Neutral,0.007099
"Brookdale Senior Living  ( BKD )  Reports Q4 Loss, Tops Revenue Estimates",20230221T235507,https://www.zacks.com/stock/news/2057177/brookdale-senior-living-bkd-reports-q4-loss-tops-revenue-estimates,AADI,0.207571,Neutral,0.0
McKesson  ( MCK )  Announces Availability of FDA-Cleared Drug for MCL,20230215T140500,https://www.zacks.com/stock/news/2054602/mckesson-mck-announces-availability-of-fda-cleared-drug-for-mcl,AADI,0.056943,Neutral,-0.055001
5 Value Stocks In The Healthcare Sector,20230130T144414,https://www.benzinga.com/news/23/01/30623123/5-value-stocks-in-the-healthcare-sector,AADI,0.200688,Somewhat-Bullish,0.304605
"Aadi Bioscience, Inc.  ( AADI )  Upgraded to Buy: What Does It Mean for the Stock?",20230106T170007,https://www.zacks.com/stock/news/2036372/aadi-bioscience-inc-aadi-upgraded-to-buy-what-does-it-mean-for-the-stock,AADI,0.357293,Somewhat-Bullish,0.309578
McKesson  ( MCK )  Announces Availability of FDA-Accepted Drug,20221223T181500,https://www.zacks.com/stock/news/2032077/mckesson-mck-announces-availability-of-fda-accepted-drug,AADI,0.068896,Neutral,-0.075458
"5 Value Stocks To Watch In The Healthcare Sector - Innoviva  ( NASDAQ:INVA ) , Vicarious Surgical  ( NYSE:RBOT ) , Walgreens Boots Alliance  ( NASDAQ:WBA ) , Aadi Bioscience  ( NASDAQ:AADI ) , Pfizer  ( NYSE:PFE ) ",20221212T144338,https://www.benzinga.com/news/22/12/30042279/5-value-stocks-to-watch-in-the-healthcare-sector,AADI,0.166169,Somewhat-Bullish,0.317226
Mirati's  ( MRTX )  Stock Rises on Q3 Earnings and Sales Beat,20221109T144700,https://www.zacks.com/stock/news/2016191/miratis-mrtx-stock-rises-on-q3-earnings-and-sales-beat,AADI,0.051221,Neutral,0.008976
"Aadi Bioscience, Inc.  ( AADI )  Reports Q3 Loss, Tops Revenue Estimates",20221109T142506,https://www.zacks.com/stock/news/2016130/aadi-bioscience-inc-aadi-reports-q3-loss-tops-revenue-estimates,AADI,0.402403,Neutral,0.074568
Aadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Presented at 2022 ASCO Annual Meeting,20220526T211000,https://www.globenewswire.com/news-release/2022/05/26/2451676/0/en/Aadi-Bioscience-Announces-Exploratory-Biomarker-Data-from-Patients-in-Its-AMPECT-Trial-and-Expanded-Access-Program-to-be-Presented-at-2022-ASCO-Annual-Meeting.html,AADI,0.037892,Neutral,0.012417
Aadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Presented at 2022 ASCO Annual Meeting,20220526T211000,https://www.benzinga.com/pressreleases/22/05/g27432018/aadi-bioscience-announces-exploratory-biomarker-data-from-patients-in-its-ampect-trial-and-expande,AADI,0.037121,Neutral,0.015475
Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference,20220518T110000,https://www.benzinga.com/pressreleases/22/05/g27271588/aadi-bioscience-to-present-at-the-h-c-wainwright-global-investment-conference,AADI,0.31006,Neutral,0.026222
UPDATE -- Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update,20220512T123200,https://www.globenewswire.com/news-release/2022/05/12/2441993/0/en/UPDATE-Aadi-Bioscience-Reports-First-Quarter-2022-Financial-Results-and-Provides-a-Corporate-Update.html,AADI,0.021936,Neutral,0.004264
"Aadi Bioscience to Announce First Quarter 2022 Financial Results on May 12, 2022",20220428T210727,https://www.benzinga.com/pressreleases/22/04/g26886185/aadi-bioscience-to-announce-first-quarter-2022-financial-results-on-may-12-2022,AADI,0.331172,Neutral,0.017365
"Aadi Bioscience to Announce First Quarter 2022 Financial Results on May 12, 2022",20220428T210700,https://www.globenewswire.com/news-release/2022/04/28/2432068/0/en/Aadi-Bioscience-to-Announce-First-Quarter-2022-Financial-Results-on-May-12-2022.html,AADI,0.356268,Neutral,0.021056
"Aadi Bioscience to Participate at the Jefferies ""Biotech on the Bay"" Summit",20220418T120000,https://www.globenewswire.com/news-release/2022/04/18/2423650/0/en/Aadi-Bioscience-to-Participate-at-the-Jefferies-Biotech-on-the-Bay-Summit.html,AADI,0.235937,Neutral,0.006721
Aadi Bioscience Announces Data Presentation on incidence of TSC1 and TSC2 Alterations in Advanced Cancers at the Annual Meeting of the American Association for Cancer Research  ( AACR ) ,20220408T170936,https://www.benzinga.com/pressreleases/22/04/g26549774/aadi-bioscience-announces-data-presentation-on-incidence-of-tsc1-and-tsc2-alterations-in-advanced-,AADI,0.09722,Neutral,0.003632
Aadi Bioscience Announces Data Presentation on incidence of TSC1 and TSC2 Alterations in Advanced Cancers at the Annual Meeting of the American Association for Cancer Research  ( AACR ) ,20220408T170900,https://www.globenewswire.com/news-release/2022/04/08/2419477/0/en/Aadi-Bioscience-Announces-Data-Presentation-on-incidence-of-TSC1-and-TSC2-Alterations-in-Advanced-Cancers-at-the-Annual-Meeting-of-the-American-Association-for-Cancer-Research-AACR.html,AADI,0.099697,Neutral,0.003962
Aadi Bioscience Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 Genes,20220331T184500,https://www.globenewswire.com/news-release/2022/03/31/2414284/0/en/Aadi-Bioscience-Announces-First-Patient-Dosed-in-its-PRECISION-1-Phase-2-Registrational-Trial-of-nab-Sirolimus-in-Patients-with-Solid-Tumors-Harboring-Pathogenic-Inactivating-Alter.html,AADI,0.052805,Neutral,0.003899
Aadi Bioscience Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 Genes,20220331T184500,https://www.benzinga.com/pressreleases/22/03/g26407717/aadi-bioscience-announces-first-patient-dosed-in-its-precision-1-phase-2-registrational-trial-of-n,AADI,0.050963,Neutral,0.003798
Aadi Bioscience: Q4 Earnings Insights,20220317T123030,https://www.benzinga.com/news/earnings/22/03/26181916/aadi-bioscience-q4-earnings-insights,AADI,0.60661,Neutral,0.001998
